A Norwegian man appears to have achieved long-term HIV remission following a stem cell transplant from his brother, marking a rare case of potential HIV cure through this approach.
The patient received stem cells from a matched sibling donor who carried a natural genetic mutation that provides resistance to HIV infection. This CCR5-delta32 mutation prevents the virus from entering and infecting CD4 cells, the immune cells HIV targets. After the transplant, the man stopped antiretroviral therapy and has remained virus-free for an extended period, suggesting the donor cells established a new immune system resistant to the virus.
This case builds on earlier findings. The Berlin Patient, treated in 2007, achieved similar results through a stem cell transplant from a donor with the same CCR5-delta32 mutation. That case demonstrated the principle works but raised questions about whether it could be replicated. The Norwegian case provides a second data point confirming stem cell transplantation from genetically resistant donors can produce durable remission.
However, stem cell transplants remain an extreme intervention. The procedure itself carries serious risks, including graft-versus-host disease, organ damage, and infection. It requires intensive chemotherapy or radiation to eliminate the diseased bone marrow first. Most HIV specialists reserve this approach for patients with concurrent blood cancers who need transplants anyway.
Modern antiretroviral therapy has transformed HIV into a manageable chronic condition for most people with access to treatment. People on effective antiretroviral regimens live normal lifespans and cannot transmit the virus sexually, a concept known as undetectable equals untransmittable (U=U).
The stem cell approach remains impractical for widespread HIV treatment. Finding matched donors with the CCR5-delta32 mutation is difficult. The mutation occurs in roughly 1 percent of Northern European populations and is rare elsewhere. Researchers continue exploring gene-